Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) has become recently more complex than ever, leaving the clinicians perplexed with outdated guidelines and emerging evidence about new LDL-C lowering therapies. 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines have focused on high intensity statin therapy for specific groups of patients, while abandoning long established LDL-C goals, a strategy which no longer seems valid. PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors have emerged as the add-on therapy on top of statins and/or ezetimibe for the treatment of hypercholesterolemia and ASCVD prevention. In several clinical trials, PCSK9 inhibitors have demonstrated their safety and robust LDL-C-lowering power. One completed cardiovascular (CV) outcomes trial (FOURIER; Further Cardiovascular Outcomes Research with PCSK9 Inhibitions in Subjects with Elevated Risk) has demonstrated that PCSK9 inhibition reduces rates of CV death as well as non-fatal stroke and MI, while another major CV outcome trial is under way (ODYSSEY-OUTCOMES). Several trials studying CV benefits of novel LDL-C-lowering therapies are also being conducted. Prompt revision of ACC/AHA guidelines is necessary. In the meantime, physicians need to use clinical judgment integrating the most recent evidence into their practice.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalPostgraduate Medicine
DOIs
StateAccepted/In press - Sep 16 2017

Fingerprint

Cardiovascular Diseases
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Guidelines
American Heart Association
Primary Prevention
Therapeutics
Group Psychotherapy
Secondary Prevention
Hypercholesterolemia
Cardiology
Stroke
Outcome Assessment (Health Care)
Clinical Trials
Physicians
Safety
Mortality
oxidized low density lipoprotein
Proprotein Convertase 9
Inhibition (Psychology)

Keywords

  • ASCVD prevention
  • cholesterol
  • Dyslipidemia
  • ezetimibe
  • guidelines
  • LDL
  • PCSK9
  • PCSK9 inhibitors
  • statins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{1bc3d9e8aa904efa8b0e0fd3853694b7,
title = "Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease",
abstract = "Primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) has become recently more complex than ever, leaving the clinicians perplexed with outdated guidelines and emerging evidence about new LDL-C lowering therapies. 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines have focused on high intensity statin therapy for specific groups of patients, while abandoning long established LDL-C goals, a strategy which no longer seems valid. PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors have emerged as the add-on therapy on top of statins and/or ezetimibe for the treatment of hypercholesterolemia and ASCVD prevention. In several clinical trials, PCSK9 inhibitors have demonstrated their safety and robust LDL-C-lowering power. One completed cardiovascular (CV) outcomes trial (FOURIER; Further Cardiovascular Outcomes Research with PCSK9 Inhibitions in Subjects with Elevated Risk) has demonstrated that PCSK9 inhibition reduces rates of CV death as well as non-fatal stroke and MI, while another major CV outcome trial is under way (ODYSSEY-OUTCOMES). Several trials studying CV benefits of novel LDL-C-lowering therapies are also being conducted. Prompt revision of ACC/AHA guidelines is necessary. In the meantime, physicians need to use clinical judgment integrating the most recent evidence into their practice.",
keywords = "ASCVD prevention, cholesterol, Dyslipidemia, ezetimibe, guidelines, LDL, PCSK9, PCSK9 inhibitors, statins",
author = "Cezary Wojcik",
year = "2017",
month = "9",
day = "16",
doi = "10.1080/00325481.2017.1376570",
language = "English (US)",
pages = "1--10",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",

}

TY - JOUR

T1 - Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease

AU - Wojcik, Cezary

PY - 2017/9/16

Y1 - 2017/9/16

N2 - Primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) has become recently more complex than ever, leaving the clinicians perplexed with outdated guidelines and emerging evidence about new LDL-C lowering therapies. 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines have focused on high intensity statin therapy for specific groups of patients, while abandoning long established LDL-C goals, a strategy which no longer seems valid. PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors have emerged as the add-on therapy on top of statins and/or ezetimibe for the treatment of hypercholesterolemia and ASCVD prevention. In several clinical trials, PCSK9 inhibitors have demonstrated their safety and robust LDL-C-lowering power. One completed cardiovascular (CV) outcomes trial (FOURIER; Further Cardiovascular Outcomes Research with PCSK9 Inhibitions in Subjects with Elevated Risk) has demonstrated that PCSK9 inhibition reduces rates of CV death as well as non-fatal stroke and MI, while another major CV outcome trial is under way (ODYSSEY-OUTCOMES). Several trials studying CV benefits of novel LDL-C-lowering therapies are also being conducted. Prompt revision of ACC/AHA guidelines is necessary. In the meantime, physicians need to use clinical judgment integrating the most recent evidence into their practice.

AB - Primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) has become recently more complex than ever, leaving the clinicians perplexed with outdated guidelines and emerging evidence about new LDL-C lowering therapies. 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines have focused on high intensity statin therapy for specific groups of patients, while abandoning long established LDL-C goals, a strategy which no longer seems valid. PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors have emerged as the add-on therapy on top of statins and/or ezetimibe for the treatment of hypercholesterolemia and ASCVD prevention. In several clinical trials, PCSK9 inhibitors have demonstrated their safety and robust LDL-C-lowering power. One completed cardiovascular (CV) outcomes trial (FOURIER; Further Cardiovascular Outcomes Research with PCSK9 Inhibitions in Subjects with Elevated Risk) has demonstrated that PCSK9 inhibition reduces rates of CV death as well as non-fatal stroke and MI, while another major CV outcome trial is under way (ODYSSEY-OUTCOMES). Several trials studying CV benefits of novel LDL-C-lowering therapies are also being conducted. Prompt revision of ACC/AHA guidelines is necessary. In the meantime, physicians need to use clinical judgment integrating the most recent evidence into their practice.

KW - ASCVD prevention

KW - cholesterol

KW - Dyslipidemia

KW - ezetimibe

KW - guidelines

KW - LDL

KW - PCSK9

KW - PCSK9 inhibitors

KW - statins

UR - http://www.scopus.com/inward/record.url?scp=85029473110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029473110&partnerID=8YFLogxK

U2 - 10.1080/00325481.2017.1376570

DO - 10.1080/00325481.2017.1376570

M3 - Article

C2 - 28879791

AN - SCOPUS:85029473110

SP - 1

EP - 10

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

ER -